EP3656377C0 - Wässrige formulierung mit paracetamol und ibuprofen - Google Patents

Wässrige formulierung mit paracetamol und ibuprofen

Info

Publication number
EP3656377C0
EP3656377C0 EP19215735.2A EP19215735A EP3656377C0 EP 3656377 C0 EP3656377 C0 EP 3656377C0 EP 19215735 A EP19215735 A EP 19215735A EP 3656377 C0 EP3656377 C0 EP 3656377C0
Authority
EP
European Patent Office
Prior art keywords
paracetamol
ibuprofen
aqueous formula
aqueous
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19215735.2A
Other languages
English (en)
French (fr)
Other versions
EP3656377B1 (de
EP3656377A1 (de
Inventor
Thomas Jacobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyloris Pharmaceuticals SA
Original Assignee
Hyloris Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyloris Pharmaceuticals SA filed Critical Hyloris Pharmaceuticals SA
Publication of EP3656377A1 publication Critical patent/EP3656377A1/de
Application granted granted Critical
Publication of EP3656377C0 publication Critical patent/EP3656377C0/de
Publication of EP3656377B1 publication Critical patent/EP3656377B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10Bag-type containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/20Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093Containers having several compartments for products to be mixed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/1407Infusion of two or more substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/19Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
EP19215735.2A 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen Active EP3656377B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2014/065544 WO2016008546A1 (en) 2014-07-18 2014-07-18 Aqueous formulation comprising paracetamol and ibuprofen
EP15738918.0A EP3169307B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen
PCT/EP2015/066466 WO2016009067A1 (en) 2014-07-18 2015-07-17 Aqueous formulation comprising paracetamol and ibuprofen

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP15738918.0A Division EP3169307B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen
EP15738918.0A Division-Into EP3169307B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen

Publications (3)

Publication Number Publication Date
EP3656377A1 EP3656377A1 (de) 2020-05-27
EP3656377C0 true EP3656377C0 (de) 2025-02-12
EP3656377B1 EP3656377B1 (de) 2025-02-12

Family

ID=51211244

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15738918.0A Active EP3169307B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen
EP19215735.2A Active EP3656377B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15738918.0A Active EP3169307B1 (de) 2014-07-18 2015-07-17 Wässrige formulierung mit paracetamol und ibuprofen

Country Status (26)

Country Link
US (5) US11219609B2 (de)
EP (2) EP3169307B1 (de)
JP (2) JP6745798B2 (de)
CN (2) CN106794163B (de)
AR (1) AR100365A1 (de)
AU (1) AU2015289035B2 (de)
BR (1) BR112017001093B1 (de)
CA (1) CA2955557C (de)
CY (1) CY1122899T1 (de)
DK (1) DK3169307T3 (de)
EA (1) EA036212B1 (de)
ES (2) ES2791349T3 (de)
HR (1) HRP20200704T1 (de)
HU (1) HUE048881T2 (de)
IL (1) IL250112B2 (de)
LT (1) LT3169307T (de)
MX (1) MX381776B (de)
MY (1) MY192813A (de)
NZ (1) NZ728796A (de)
PL (2) PL3656377T3 (de)
PT (1) PT3169307T (de)
RS (1) RS60289B1 (de)
SG (1) SG11201700421RA (de)
SI (1) SI3169307T1 (de)
TN (1) TN2017000011A1 (de)
WO (2) WO2016008546A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
JP7386080B2 (ja) * 2016-08-02 2023-11-24 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物
DE102017202510A1 (de) 2017-02-16 2018-08-16 Eurozyto Gmbh Behältnis zur Bereitstellung patientenspezifischer Arzneimittel
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
WO2022178018A1 (en) * 2021-02-19 2022-08-25 Nevakar Injectables Inc. Liquid unit dosage forms for treatment of pain
CN117241790A (zh) * 2021-04-28 2023-12-15 葛兰素史克消费保健(美国)控股有限责任公司 不相容活性药物成分的碱金属盐组合
CN114062554B (zh) * 2021-11-20 2023-07-21 山东百诺医药股份有限公司 一种同时测定对乙酰氨基酚布洛芬有关物质的分析方法
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
GR1011104B (el) * 2024-12-18 2026-01-16 Ιουλια Τσετη Προγεμισμενη συριγγα υδατικου διαλυματος παρακεταμολης καταλληλη για ενεσιμη χορηγηση

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US20060100578A1 (en) * 2004-09-13 2006-05-11 Tandem Medical, Inc. Medication delivery apparatus and methods for intravenous infusions
JP2011508768A (ja) * 2008-01-03 2011-03-17 ウォックハート リサーチ センター パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤
US20110166234A1 (en) 2008-10-14 2011-07-07 Atkinson Hartley Campbell Medicinal product and treatment
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
US8404748B2 (en) * 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
DK2389923T3 (da) * 2010-05-19 2013-03-18 Uni Pharma Kleon Tsetis Pharmaceutical Lab S A Stabil klar til brug injicerbar paracetamol-formulering
US20130225685A1 (en) * 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
BE1020614A5 (nl) 2012-01-27 2014-01-07 Hubert De Backer Nv Injectiespuit.
WO2013138628A2 (en) * 2012-03-16 2013-09-19 Cumberland Pharmaceuticals, Inc. Injectable ibuprofen formulation
US9072661B2 (en) * 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF

Also Published As

Publication number Publication date
CN113018258A (zh) 2021-06-25
IL250112A0 (en) 2017-03-30
MY192813A (en) 2022-09-09
SI3169307T1 (sl) 2020-07-31
CN106794163B (zh) 2021-03-26
HRP20200704T1 (hr) 2020-07-24
AU2015289035B2 (en) 2020-03-26
AU2015289035A1 (en) 2017-02-23
MX2017000764A (es) 2017-08-18
IL250112B (en) 2022-10-01
NZ728796A (en) 2023-05-26
ES3013411T3 (en) 2025-04-11
EA036212B1 (ru) 2020-10-14
EA201790223A1 (ru) 2017-05-31
PL3656377T3 (pl) 2025-05-26
AR100365A1 (es) 2016-09-28
CA2955557A1 (en) 2016-01-21
US20230181502A1 (en) 2023-06-15
BR112017001093B1 (pt) 2023-01-31
EP3656377B1 (de) 2025-02-12
US20250064764A1 (en) 2025-02-27
WO2016008546A1 (en) 2016-01-21
US11389416B2 (en) 2022-07-19
TN2017000011A1 (en) 2018-07-04
WO2016009067A1 (en) 2016-01-21
CY1122899T1 (el) 2021-05-05
SG11201700421RA (en) 2017-02-27
LT3169307T (lt) 2020-07-10
ES2791349T3 (es) 2020-11-04
US20220031645A1 (en) 2022-02-03
PT3169307T (pt) 2020-05-18
BR112017001093A2 (pt) 2017-11-14
JP6745798B2 (ja) 2020-08-26
US12083087B2 (en) 2024-09-10
RS60289B1 (sr) 2020-07-31
JP2017522382A (ja) 2017-08-10
US11213498B2 (en) 2022-01-04
PL3169307T3 (pl) 2020-09-21
JP2020059740A (ja) 2020-04-16
US11219609B2 (en) 2022-01-11
CA2955557C (en) 2021-06-22
EP3656377A1 (de) 2020-05-27
US20190343785A1 (en) 2019-11-14
CN106794163A (zh) 2017-05-31
US20170209398A1 (en) 2017-07-27
MX381776B (es) 2025-03-13
IL250112B2 (en) 2023-02-01
DK3169307T3 (da) 2020-05-11
HUE048881T2 (hu) 2020-08-28
EP3169307A1 (de) 2017-05-24
EP3169307B1 (de) 2020-02-19
JP6892494B2 (ja) 2021-06-23

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
EP3205103C0 (de) Intrarundfunk und intervereinigung
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
IL246978A0 (en) Novel pharmaceutical formulations
DK3192451T3 (da) Medicinsk krog
EP3285633A4 (de) Lenkbares mikroendoskop
EP3164406C0 (de) Borsäurederivate und therapeutische verwendungen davon
EP3634324C0 (de) Stomaring mit hautfreundlichen substanzen
EP3656377C0 (de) Wässrige formulierung mit paracetamol und ibuprofen
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
HUE040395T2 (hu) Ápolóeszköz és eljárás
DK3197354T3 (da) Medicinsk anordning
HUE058200T2 (hu) Végtag-érszorító
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK2918305T3 (da) Forskudt kateterfastgørelsesindretning
EP3193805A4 (de) Tragbarer rollstuhl mit doppelkonfiguration
IL258856A (en) Solabegron zwitterion and uses thereof
HUE048503T2 (hu) Dihidropirimidin-2-on vegyületek és gyógyszerészeti alkalmazásai
EP3108285C0 (de) Anzeigevorrichtung mit verbessertem kontrast
DK3191148T3 (da) Lægemiddelindretninger med reduceret thrombogenicitet
DK3140050T3 (da) Dosering med visning
DK3190964T3 (da) Spirometer
ITUA20161992A1 (it) Sumo e suoi utilizzi
DK3193936T3 (da) Antimikrobielle midler med forøget virkning
DE202014105547U8 (de) Steckverbinder und Steckverbindung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3169307

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201126

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220428

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HYLORIS PHARMACEUTICALS SA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230421

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240924

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 3169307

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015091017

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250306

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3013411

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20250411

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_11998/2025

Effective date: 20250311

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250314

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250317

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250512

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250527

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250526

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250612

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250526

Year of fee payment: 11

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 11

Effective date: 20250714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250804

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250801

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20251113